Regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy-resistant MSS metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Fakih, Marwan
Sandhu, Jaideep Singh
Lim, Dean
Li, Sierra
Wang, Chongkai
机构：
[1] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[2] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [31] Regorafenib for metastatic Colorectal Cancer?
    Bossenmayer, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (12) : 563 - 563
  • [32] Regorafenib in metastatic colorectal cancer
    Sartore-Bianchi, Andrea
    Zeppellini, Annalisa
    Amatu, Alessio
    Ricotta, Riccardo
    Bencardino, Katia
    Siena, Salvatore
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (03) : 255 - 265
  • [33] A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
    Cho, May Thet
    Lim, Dean
    Synold, Timothy W.
    Frankel, Paul Henry
    Leong, Lucille A.
    Chao, Joseph
    Chung, Vincent M.
    Chen, Yuan
    Sentovich, Stephen
    Luevanos, Eloise
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Regorafenib for metastatic colorectal cancer
    Andre, Thierry
    Raymond, Eric
    de Gramont, Aimery
    LANCET, 2013, 381 (9877): : 1536 - 1537
  • [35] Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
    Andre, Thierry
    Elez, Elena
    Van Cutsem, Eric
    Jensen, Lars Henrik
    Bennouna, Jaafar
    Mendez, Guillermo
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Lenz, Heinz-Josef
    Manzano Mozo, Jose Luis
    Tortora, Giampaolo
    Garcia-Carbonero, Rocio
    Dahan, Laetitia
    Chalabi, Myriam
    Joshi, Rohit
    Goekkurt, Eray
    Braghiroli, Maria Ignez
    Cil, Timucin
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Dixon, Matthew
    Abdullaev, Sandzhar
    Lonardi, Sara
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (21): : 2014 - 2026
  • [36] Impact of site of metastases on response to immunotherapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Fakih, Marwan
    Sandhu, Jaideep
    Li, Xiaochen
    Wang, Chongkai
    CANCER RESEARCH, 2023, 83 (07)
  • [37] Cases in the Management of Metastatic Colorectal Cancer: Use of Regorafenib as a Bridge to Chemotherapy
    Marshall, John L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 2 - 7
  • [38] Total lesion glycolysis (TLG) as an imaging biomarker of regorafenib treatment in metastatic colorectal cancer (mCRC)
    Lim, Yoojoo
    Bang, Ji-In
    Han, Sae-Won
    Paeng, Jin Chul
    Yoon, Jeong Hee
    Lee, Jeong Min
    Won, Jae-Kyung
    Kang, Gyeong Hoon
    Jeong, Seung-Yong
    Park, Kyu Joo
    Lee, Kyung-Hun
    Kim, Jee Hyun
    Kim, Tae-You
    CANCER RESEARCH, 2016, 76
  • [39] Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy
    Wong, Adriana J.
    Finch, Lindsey
    Pearson, Joseph Matt
    Pinto, Andre
    Huang, Marilyn
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 40
  • [40] Predictive value of CDC37 gene expression for regorafenib in metastatic colorectal cancer (mCRC)
    Arai, Hiroyuki
    Denda, Tadamichi
    Kubota, Yohei
    Takeda, Hiroyuki
    Doi, Ayako
    Horie, Yoshiki
    Umemoto, Kumiko
    Izawa, Naoki
    Sunakawa, Yu
    ANNALS OF ONCOLOGY, 2023, 34 : S1407 - S1407
12345